Amorolfine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Amorolfine: From Onychomycosis to Drug-Induced Osteoporosis
One-Sentence Summary
Amorolfine is a morpholine-class topical antifungal, best known for treating onychomycosis (fungal nail infections) via nail lacquer formulation. The TxGNN model predicts it may have potential for Drug-Induced Osteoporosis as the top-ranked indication, however this is currently supported by 0 clinical trials and 0 publications — the evidence base is entirely model-prediction only, and all 10 predicted indications across this batch share this L5 status.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Onychomycosis (fungal nail infections) |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.9978% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Amorolfine is a morpholine-class antifungal that inhibits ergosterol biosynthesis in fungal cell membranes — specifically targeting the enzymes Δ14-reductase and Δ7→Δ8-isomerase. This disrupts membrane integrity and kills the fungal cell. It is formulated exclusively as a topical nail lacquer, resulting in negligible systemic absorption. This pharmacokinetic profile is critical: systemic exposure following topical application is essentially non-existent.
The mechanistic rationale for drug-induced osteoporosis is extremely weak. While certain azole antifungals (particularly itraconazole) have shown indirect interference with sterol-dependent bone metabolism pathways, amorolfine belongs to the morpholine class — a fundamentally different chemical scaffold with no established Hedgehog pathway, CYP enzyme, or osteoclast/osteoblast interaction. Cross-class extrapolation from azoles to morpholines is not scientifically justified.
Even if a sterol-bone metabolism link were biologically plausible, amorolfine’s near-zero systemic bioavailability from topical use makes any systemic pharmacological effect clinically irrelevant. The TxGNN prediction most likely reflects a topological artifact within the knowledge graph — ergosterol/sterol metabolism nodes are structurally adjacent to bone-related pathways — rather than a genuine drug-disease pharmacological signal. Of the 10 predictions in this batch, only urethral disease (rank 10) carries even a minimal mechanistic connection (fungal urethritis), and the topical delivery barrier applies there as well.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: All 10 TxGNN-predicted indications for Amorolfine are rated L5 (model prediction only, zero supporting clinical or preclinical evidence), and Amorolfine’s exclusive topical formulation with negligible systemic exposure represents a fundamental pharmacokinetic barrier to any systemic repurposing hypothesis. The drug is also not currently registered or marketed in India, meaning there is no existing regulatory pathway to leverage.
To proceed, the following is needed:
- Retrieve the original approved indication(s) from the drug’s package insert or regulatory filings (CDSCO / EMA / originator label) to complete the baseline drug profile
- Obtain detailed mechanism of action data (MOA) from DrugBank API to enable mechanistic plausibility analysis
- Determine whether a systemic oral or IV formulation of amorolfine exists in any jurisdiction — without a systemic delivery route, all current predictions remain clinically inaccessible
- Consider whether any predicted indication could theoretically be addressed via local/topical delivery (e.g., fungal urethritis as a topical application), which is the only scenario with minimal biological plausibility in this batch
- Collect TFDA/CDSCO package insert warnings and contraindications to complete the S1-level safety assessment before any further development discussion
- If the program continues, prioritise the mechanistic re-evaluation of urethral disease (rank 10) as the sole candidate with a tenuous but existing biological rationale, contingent on resolving the delivery route question
⚠️ Research Disclaimer: This report is for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.